ZYME Stock Price
Zymeworks Inc.
ZYME stock price is $25.95 (+4.74% on the day), giving Zymeworks Inc. a market cap of $1.78B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
ZYME Stock Overview
- Price
- $25.95
- Previous close
- $24.77
- Open
- $25.19
- Market cap
- $1.78B
- P/E ratio
- -21.9
- 52-week range
- $16.00 - $31.34
- 1-year price target
- $40.93
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 55
About Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ZYME | $25.95 | +4.7% | 207.23K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |